Deutsche Bank lowered the firm’s price target on Genmab (GMAB) to DKK 2,250 from DKK 2,500 and keeps a Buy rating on the shares.

Assetmark Inc. boosted its stake in shares of Genmab A/S (NASDAQ:GMAB – Free Report) by 16.2% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 82,629 shares of ...

GEN1047, GEN3017, and GEN1056—to refocus resources, following its recent $1.8 billion acquisition of ProfoundBio. The move ...

Hello, and welcome to Genmab's Financial Results Conference Call for the First Nine Months of 2024. As a reminder, this conference call is being recorded. During this telephone conference ...

Analysts' ratings for Genmab (NASDAQ:GMAB) over the last quarter vary from bullish to bearish, as provided by 10 analysts. The following table provides a quick overview of their recent ratings ...

TD Cowen analyst Yaron Werber has maintained their neutral stance on GMAB stock, giving a Hold rating yesterday. Yaron Werber has given his ...

Denmark stocks were lower after the close on Thursday, as losses in the Real Estate, Personal & Household Goods and ...

Denmark equities were lower at the close on Thursday, as losses in the Copenhagen Real Estate, OMX Copenhagen Personal & Household Goods PI and Copenhagen Health Care sectors led shares lower. At the ...

Genmab A/S (NASDAQ:GMAB – Free Report) – Research analysts at William Blair raised their FY2024 earnings per share (EPS) estimates for shares of Genmab A/S in a note issued to investors on ...

GSK's drive to resurrect its multiple myeloma therapy Blenrep has continued with new data from the DREAMM-7 trial showing an ...

The marketing applications with the EMA and FDA are for J&J and partner Genmab's Darzalex Faspro version of the anti-CD38 ...